About the Report:
Japan is among the most developed industrialised nations in terms of science and technology (S&T). As innovation in industrial biotechnology is of long-standing priority in the national S&T policy, Japanese companies, often supported by large international trading houses or by governmental institutions, are continuously on alert for innovations abroad. This constitutes an excellent opportunity for European start-ups and SMEs which develop innovative products or technologies to partner with Japanese stakeholders. However, large distances and different business cultures must be patiently bridged to succeed in business development. Thus, this report titled 'Industrial (“White”) Biotechnology in Japan: Company Activities and Government Programs – and How to Become Involved. A Primer for European SMEs' describes some of the mechanisms by which European SMEs can get involved and how such partnering can be achieved.
About the Expert
Rolf SCHMID, Senior Consultant & CEO, Bio4Business - SCHMID Rolf
The recording of the past webinar covering this topic is available for online viewers here. (Once you are logged in, look for the link below the "After event information")
Picture: Forest - National Museum of Nature and Science, Tokyo
Copyright: Wikipedia in the public domain
How is Japanese biotech R&D structured, who are the key stakeholders, and how can European SMEs profit and find Japanese partners? Japan spends consistently over 3% of its GDP on R&D, of which some 70
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
Hundreds of web pages with up-to-date information on Japan, more than 400 market reports and recorded webinars available as well as a lot of detailed information on Japanese business culture.